English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Purpose of the study HIV treatment guidelines state that the goal of highly active antiretroviral therapy (HAART) is to achieve an undetectable viral load (VL; <50 copies/mL) in HIVinfected patients. Two new therapies, etravirine (ETR; TMC125) and raltegravir (RAL), have recently been approved in the US, both with similar indications for treatment-experienced HIV-1-infected patients. This analysis compared the relative cost of reaching this treatment goal for each therapy.

Cost-minimisation analysis of the use of etravirine or raltegravir in treatment-experienced HIV-1-infected patients